Abstract: Psoriasis is a chronic immunologic disease characterized by red papules and plaques with a silver colored scale. The impact of psoriasis on patients' overall quality of life is significant, broad, and deep, including effects on emotional wellbeing, psychological stress, self-esteem, relationship, work, social activities, financial burden, and even physical function. Although there are various measures available for assessing health-related quality of life (HRQoL) in research studies, there is no consensus on which measure is best to use in clinical practice or for research comparing different treatments. Choosing treatments based on patients' specific individual preferences, goal-orientation, and close, attentive cooperation between patients and their doctors may be an effective strategy that can be applied to improve patients' quality of life.
Introduction
Psoriasis is a chronic immunologic disease characterized by red papules and plaques with a silver colored scale. 1, 2 Psoriasis affects about 0.6%-4.8% of the world population and roughly 2.2% of the US population. In the US, there are about 250,000 new cases of psoriasis annually. 3, 4 The total direct cost of psoriasis is above US$1 billion. 5 The estimated incremental cost is US$1500 per year, with 40% of this considered as indirect costs. 6 This statistical description of psoriasis does not clearly capture the full impact of psoriasis on patients' lives.
Although psoriasis usually isn't a life-threatening condition (accepting cardiovascular and psychiatric comorbidities) and can be treated in the outpatient setting, it is a challenging and frustrating condition for patients and often for their physicians as well. Treatments are chronic and sometimes complicated. Commonly, treatment incorporates combinations of different treatment options -such as topical treatments, phototherapy, and systemic treatments -as well as different treatments for different areas of the body that are affected. 7 Treatment planning is further complicated by the need to take into consideration patients' individual preferences, expectations, and quality of life (QoL). Besides the complexity of treatment, there are some other management challenges in the treatment of psoriasis such as poor adherence to treatment, risk of comorbidities, childhood psoriasis, and lifestyle modification and maintenance. 1, 8, 9 The impact of psoriasis on the lives of patients The impact of psoriasis on patients' overall QoL is broad and deep, including effects on emotional wellbeing, psychological stress, self-esteem, relationships, work, social activities, financial burden, and even physical function ( particularly in patients with coexistent psoriasis arthritis). [10] [11] [12] The disability caused by psoriatic is comparable to that caused by other major medical conditions. 13 A 2008 National Psoriasis Foundation survey found that 71% of psoriasis patients agreed that psoriasis is a significant issue in everyday life. 12 It is very common for psoriasis patients to have feelings of embarrassment, stigma, and discomfort in public because they think others may judge them by their disfigurement. Based on a recent survey, around 35% of patients avoid social activities or limit dating or intimate relationships. 12 Psoriasis may reduce work productivity and is associated with a negative impact at work as measured by the Work Productivity Assessment Index. 14 In more severe cases, including those with significant psoriatic arthritis (which attacks approximately a quarter of the psoriasis population), patients often experience physical dysfunction, which is associated with work disability and can cause more reduction in QoL. 15 Absenteeism is another large concern for psoriasis sufferers. Due to the disease, patients with psoriasis experience more missed work days than healthy people, further contributing to indirect cost and additive economic burden. 16 Psoriasis causes emotional stress, impairment of selfesteem, and mood disorders such as depression. More than half of patients (57%) think that psoriasis negatively affects their self-esteem. 12 One study reported about 50% and 30% of the psoriasis population had depression scores and anxiety scores, respectively, even higher than individuals with psychiatric problems. 17 Depression is now even regarded as an important comorbidity along with psoriasis. The effects on self-esteem, emotional stress, and daily life increase the psychological burden of the disease, and may lead to depression and suicidal ideation in some cases. 13, 18 A study indicated that, among 127 psoriasis sufferers, 9.7% claimed active suicidal ideation, and 5.5% stated their wish to be dead because of their psoriasis.
19

Review of measurements of the QoL in psoriasis patients
Psoriasis can be measured using objective measures of the extent and severity of the skin disease, but these measures do not capture the impact of the disease on patients' lives. Objective measures such as the extent of body surface area affected or the psoriasis area severity index (PASI) are commonly used as primary outcomes in clinical trials. These objective indicators of clinical response do correlate, though not tightly, with measures of patients' health-related QoL (HRQoL). 20 By capturing HRQoL data along with objective measures of skin involvement, a more complete picture of the impact of the disease and of improvements with treatment can be obtained. Various tools can be used to assess psoriasis severity and HRQoL. These measures are classified as psoriasis-specific, skin-specific, generic, and "mixed." 21 The following section illustrates each classification with some validated, commonly used instruments. The general characteristics of QoL measures in psoriasis vary (Table 1) . Generally speaking, the psoriasis-specific measures are the most sensitive for identifying the impact of the disease. Generic measures are widely used in clinical trials because they permit comparisons across different diseases and help rule out the possibility that treatments that are effective for the skin are reducing patients' QoL in other dimensions. 21 For assessing disease for research purposes, it is very common to use a combination of these measures, such as a specific along with a generic one. For example, the European consensus group recommended and obtained a consensus on setting up treatment goals on changes in PASI and dermatology life quality index (DLQI) scores.
10 Table 2 illustrates the applications of different QoL measurements of psoriasis in clinical trials. [34] [35] [36] 38, [50] [51] [52] 54 Psoriasis-specific measures
Psoriasis disability index (PDI)
The PDI is a psoriasis-specific measure to assess patient's health-related QoL, and it is a 15-item scale. It includes areas of daily activities, personal relationship, work or school, treatment, and leisure. Even though its psychometric characteristics have been partially tested in the UK, studies show that PDI is not an optimal measure in US patients, and that psychometric properties need to be studied in the US population. 22 Psoriasis area and severity index (PASI) and self-administered PASI (SAPASI) PASI and SAPASI are important and widely used measurements for assessing the severity of psoriasis skin involvement. PASI assesses four body regions: the head (10% of the total body surface area), the upper extremities (20%), the trunk (30%), and the lower extremities (40%). The PASI score ranges from 0 to 72, with higher score representing higher severity. 23 The SAPASI is a simplified version of PASI; it uses the same criteria as the PASI but contains a silhouette of a body for patients to shade in the affected areas and three visual scales for assessing the symptoms of the regions. 24 PASI and SAPASI don't directly assess the QoL but they can correspond to the measurement of the HRQoL; when submit your manuscript | www.dovepress.com there is a 75% improvement in PASI (∆PASI $ 75), good improvement in QoL is generally seen. 20 Psoriasis index of quality of life (PSORIQoL)
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PSORIQoL is a psoriasis-specific QoL measure which is based on the needs model and developed by qualitative interviews with psoriasis patients in three different countries in Europe. It contains 25 dichotomous items, and it's short and easy for patients to complete. PSORIQoL examines the impact on the QoL in psoriasis patients rather than assesses the symptoms or functioning. 25 
Skin-specific measures
Dermatology life quality index (DLQI)
The DLQI is the first specific HRQoL questionnaire for skin disease and is currently one of the most frequently used QoL questionnaires in psoriasis or other skin disease studies. It includes ten questions regarding symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment, with each question scoring a four-point scale. Higher DLQI score indicates worse effect on QoL.
All questions are related to "the last week," and it is used in patients greater than 16 years old. The DLQI is patient friendly, well validated, and clinically interpretable, yet it may report noncomparative outcomes in different cultures, genders, and other subpopulations. 26 Because it has been widely used in the past, the effects of newer treatments on DLQI can be compared with existing agents. Despite its limitations, DLQI is one of the best measures for QoL in psoriasis.
Dermatology quality of life scale (DQOLS)
The DQOLS is a self-reported skin disease specific measure, mainly focused on the impact of skin diseases on patients' psychosocial functioning and everyday activities. It consists of 17 psychosocial items and 12 activities items, which were assigned five-point scales. The psychosocial functioning section includes embarrassment, despair, irritableness, and distress, and the activity section includes everyday, summer, social, and sexual. It may facilitate comparisons among effects of different skin disorders and among different populations regardless of age, sex, socioeconomic status, and ethnicity. The Dutch translation of PDI was used to assess QoL, and score was transformed to 0-100-point to facilitate interpretation. It was applied to assess treatment-induced disability, thus SIP was also administered to cover the emotional domain. The questionnaires were administered in three groups (short contact dithranol versus UvB phototherapy versus inpatient dithranol) at four time points (start of treatment, end of treatment, 3 months follow-up, and end of study)
Short contact dithranol treatment and UvB phototherapy improved QoL significantly (P , 0.001). Inpatients experienced reduced QoL, but treatment showed no significant improvement in QoL directly PASI PLUTO study 35 PASI and SAPASI were both used to determine the severity of disease. The proportion of patients with a 50% or more improvement of the baseline PASI or SAPASI was measured as the main outcomes measure of effectiveness of treatments (home UvB phototherapy versus outpatient UvB therapy). Another outcome measured was the percentage reduction in median PASI and SAPASI scores
The declines in PASI and SAPASI scores in both groups were significant (P , 0.001) and similar across groups (P . 0. SF-36 was used to assess HRQoL of psoriasis patients in both the adalimumab group and the placebo group. The scores were compared with US population norms at baseline and week 16. The change of 2-3 points was considered as the minimum significant difference when compared with the general US population
The improvement in QoL associated with adalimumab was to levels that were similar to or greater than those of the general US population (P , 0.001) EQ-5D CRYSTEL study 41 EQ-5D was used to assess the QoL of psoriasis patients in the continuous etanercept group and the paused etanercept group. Baseline scores in both groups were measured, and the difference of scores was also measured at the end of treatment (week 54). EQ-5D utility score ranges from 0 (death) to 1 (perfect health), and a change of 0.05 was regarded as clinically meaningful. A change of 4-8 points in the vAS part of the EQ-5D was considered as clinically meaningful 
Skindex-29, Skindex-17
The Skindex-29 is a widely studied skin disease specific QoL measurement tool. It contains 29 questions in the areas of burden of symptoms, functioning, and emotional domains, with a five-point Likert scale; the higher the Skindex-29 score the worse effect on QoL. The Skindex-17 is a Rasch-reduced version of Skindex-29, and it has two independent scores utilized in measuring skin disease related QOL. Although they are not as widely used as the DLQI, these measures have good psychometric properties and cross-cultural validation.
26,28
Generic QoL measures
Short form 36 (SF-36)
The SF-36 is a self-reported, 36-item, generic health survey which can be used across age groups ($18 years old), multiple disease states, and different treatment options. 26 It contains eight sections, including vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each scale can be scored from 0 to 100, and the higher the score the higher the QoL. 21 It is well validated, clinically interpretable, and culturally and linguistically adaptable. 28 The limitation of SF-36 is that it mainly focuses on physical functioning in areas that may not be affected by skin disease. Therefore, it's often recommended to use SF-36 with a skin-specific or psoriasis-specific tool when measuring QoL in psoriasistreatment studies.
EuroQol 5D (EQ-5D)
The EQ-5D is a self-reported generic preference-based instrument developed by the EuroQol Group to assess general health status. It is easy and quick for patients to complete and appropriate for mail surveys, in-clinic use, and face-to-face interviews. 29 It can be used across countries. It consists of areas of mobility, self care, usual activity, pain/discomfort, and anxiety/depression. Using a formula which is based on the valuation of EQ-5D health states from general population samples, EQ-5D health state date can be converted to a summary index. 29 The second part of EQ-5D is a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom. 29 This part is designed only for research on valuing health. 29 The disadvantage of EQ-5D in use of psoriasis assessment is that it is a measurement tool of general health status rather than HRQoL. In addition, it is not that sensitive when used in a specific disease. As a result, using another skin-specific measure or psoriasis-specific measure along with EQ-5D in assessing the QoL in psoriasis sufferers is suggested.
Mixed QoL measures Salford psoriasis index (SPI)
The SPI is designed to assess psoriasis severity but does so from a holistic perspective; it also takes psychosocial disability into consideration. It is derived from the similar concept as the TNM (tumor/nodes/metastasis) cancer staging classification and has a measure for three categories: signs, psychosocial disability, and interventions. It has high reliability and validity and is sensitive to change. The signs are scores converted from PASI. The psychosocial disability is a visual analogue scale which assesses the impact of psoriasis on the patient's everyday life. The interventions are extra points added because of historical disease severity. 30 
Koo-Menter psoriasis instrument (KMPI)
The KMPI is an important instrument for therapeutic decision making from both the patient's and physician's perspectives and is also a good record for the third-party payers. 31 It is divided into two parts, completed by patient and physician, respectively. Although the questions are easy to understand and answer, the questionnaire is very thorough in content, which not only contains HRQoL index but also a psoriasis quality of life index (PQOL-12) and other measurements. 32 The questions are mainly related to "the past month."
Choosing the appropriate measure of QoL in psoriasis patients can be based on: 30 (1) the reason for use (for example, if the measurement is used to compare the effect on psoriasis with other nonskin diseases, a generic QoL measure seems to be more appropriate; if the purpose is to compare the effect on psoriasis with another skin disease, a skin disease specific measure may be superior due to better sensitivity and specificity), (2) validity and reliability of the measure, (3) time context of the measure (the frequency of using a measure may depend on the time context of the questionnaire; some measures ask questions related to the last week, while some relate to the past month), (4) settings (whether in mail survey, busy clinic setting, or face-to-face interview, we can choose either short simplified form or a detailed complicated version depending on the situation), and (5) language and culture equivalence. 30 In all, no single tool is ideal for all QoL measurement needs, each having its own advantages and limitations.
Summary of current therapies available and impact on QoL
There are many currently available treatment options for psoriasis ( Table 3 ). The array of treatment is very broad, encompassing topical medications, physical treatments (phototherapy), and different types of systemic treatments. A host of potential different combinations of these can be made. Choosing among these many treatments is based on the severity, comorbidities, patient's preference, efficacy, and patient-specific clinical response to the treatment. 1 Treatment decisions are all the more complicated because the treatments themselves may adversely affect QoL; for some patients, use of prescribed treatments may be worse than the disease (a recipe that almost guarantees poor adherence).
For mild to moderate plaque psoriasis, topical therapy is generally recommended. Topical corticosteroids, emollients, and vitamin D analogs are first-line treatments. There are additional topical therapies, including coal tar, tazarotene (topical retinoids), and anthralin. To get better clinical response while minimizing adverse effects, combinations of topicals may be prescribed, and localized phototherapy is another option. 1 Although combinations of topicals could significantly improve patients' QoL, 33 all of these topical approaches are limited by the time consuming, and sometimes messy or smelly nature of topical treatment. For moderate-to-severe plaque psoriasis, phototherapy is recommended to be initiated first if feasible. 1 Topical therapies may be administered as adjunct therapy, especially for recalcitrant lesions. The most effective wavelength of ultraviolet (UV) for psoriasis is in the range of 311-313 nm (narrowband UVB). Phototherapy is effective at clearing psoriasis and may result in long remissions; phototherapy is also among the safest treatment options for long-term control of severe psoriasis. 21 Oral retinoids are often combined with UVB or UVA phototherapy because of synergies. 7 Prins et al showed short contact dithranol treatment could improve QoL significantly (Sickness Impact Profile 68, P , 0.05; PDI, P , 0.001) and similar results showed in the UVB phototherapy treatment group. 34 Additionally, the PLUTO study showed patients' QoL increased equally in office-based phototherapy and home phototherapy. 35 However, office-based phototherapy is not convenient or affordable for some patients, and the time consuming nature of this approach adds to the burden of the disease. Home phototherapy may make phototherapy more accessible for some patients and further resultes in greater patients' satisfaction. 35 Systemic agents are recommended for more extensive or refractory cases, termed moderate-to-severe psoriasis, along with psoriatic arthritis.
1 Systemic agents can include photochemotherapy, oral agents such as retinoids, methotrexate, cyclosporine, and biological immune modifying agents such as alefacept, adalimumab, etanercept, infliximab, and ustekinumab. 1 These biological immune modifying agents consistently showed significant improvement in QoL in psoriasis patients. [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Although biological agents are effective for psoriasis, the cost and potential for long-term side effects are limitations of biological agents used for psoriasis. Nevertheless, biologic treatments have been a tremendous advance in the treatment of psoriasis, offering patients with severe disease much better tolerated options, ones that have a large effect on improving patients' QoL.
The efficacy of current therapeutic treatment options for psoriasis is often examined or compared by using the results obtained with QoL measurement tools in clinical trials (Table 4) . [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [51] [52] [53] [55] [56] [57] Comparing the efficacy of different treatments is complex, however, due to the use of different outcome measurements. None of the available QoL measures are perfect for both clinical practice and research purposes. Even if a new QoL measure which is specific to psoriasis, adequate in psychometrics, cross-culturally equivalent, and can offer comparative outcomes in different clinical studies were found, it would still have the disadvantage of not being comparable to the large amount of data already collected in past clinical trials with existing QoL measures.
Conclusion and future directions
Drug development for psoriasis is an exciting area of research in dermatology, with future directions in the areas of genetic determinants, targets of potential drugs, new approaches on treatment management, and new concepts or measurement tools related to QoL in psoriasis patients.
Psoriasis has considerable genetic determinants. The association of several candidate genes with psoriasis has been corroborated. 46 Performing genome-wide association scans in psoriasis to further define the genetic determinants of psoriasis, to identify new targets, and to provide pharmacogenomic information for choosing treatment is a promising area. 1 The development of small molecular oral treatments for psoriasis is expected to help address the QoL limitations of injectable treatment.
Nanotechnology applications are being developed in the management of skin disease and are one of the promising directions which can improve pharmaceutical delivery at targeted sites and reduce side effects. New nanotechnologybased formulations such as nanoparticles are expected to be beneficial for topical agents applied in psoriasis. For example, nanoencapsulated retinoids can lead to less irritation since they have more stable properties and controlled, sustained release. 47 Encapsulated topical steroids that are currently under development could also be very useful in the management of psoriasis. They could to a large extent reduce the risk of the systematic side effects of topical steroids by making the drug build up in the epidermis and not penetrate the dermis. 47 The European consensus group is working on developing and implementing the new approach of "targeted-treatment, early intervention and the use of treatment goals" in treating psoriasis. 10 Goal-oriented treatment management has been successfully applied to other chronic diseases such as diabetes and rheumatoid arthritis in the last decade. It may assist and guide in treating psoriasis and improve health outcomes. This treatment management method involves a treatment plan, clinical response monitoring, and appropriate adjustment of the treatment if there is a gap between the clinical response and goal. To implement this approach and accomplish the best outcome, strategies for overcoming the barriers, recruiting a multidiscipline health care provider team to collaborate, and most importantly, getting patients actively involved in this process are needed. A novel concept called "Cumulative Life Course Impairment (CLCI) is helpful for understanding the burden of psoriasis." 48, 49 The CLCI concept is that impairment of QoL in psoriasis patients is cumulative and can lead to failure to achieve a "full life potential." CLCI may be used as a surrogate marker to assess the cumulative impact of psoriasis and biopsychosocial outcomes over patients' life course. 48, 49 Not only will CLCI take the cumulative effect on QoL into consideration, it will also extend the effect to comorbidities as well. In this way, we may have a potential gold standard measure of the cumulative effect on psoriasis patients' QoL. It may be helpful to learn the rationale for the earlier treatment strategies in psoriasis.
Psoriasis is an incurable chronic immune disorder that affects patients' QoL significantly and often dramatically. Although there are various measures available for assessing QoL in research studies, there is no consensus on which one is best to use in clinical practice or for research comparing different treatments. Choosing treatments based on patients' specific individual preferences, goal-orientation, and close, attentive cooperation between patients and their doctors may be an effective strategy that can be applied to improve patients' QoL.
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